Acorda Therapeutics Inc

Acorda Therapeutics — Q4 2022 Earnings Presentation

20 slides from Acorda Therapeutics's earnings presentation, Mar 9, 2023

  1. Slide 1: Acorda Therapeutics 2022 Q4 YE Earnings Call

    Acorda Therapeutics 2022 Q4 YE Earnings Call March 9, 2023

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncerta

  3. Slide 3: 2022 / Early 2023 Accomplishments

    2022 / Early 2023 Accomplishments 2022 2023 INBRIJA Licensed Long term Paid December Re-negotiated INBRIJA commercialization preclinical financial interest payment INBRIJA commercial agreement with asset to guidance in cash, not manufacturing launch in Spain Biopas for Latin Asieris provided shares

  4. Slide 4: Inbrija capsules

    ng capsules

  5. Slide 5: INBRIJA Net U.S. Sales – Q4 and YE 2022

    INBRIJA Net U.S. Sales – Q4 and YE 2022 $28M $9M Q4 2022 2022 net sales net sales 13.1% < Q4 2021 5.6% < 2021 146% > Q1 2022 2022 Guidance $27.8M - $28.7M 5 2022 Q4/YE EARNINGS

  6. Slide 6: INBRIJA U.S. Trends Since Launch

    INBRIJA U.S. Trends Since Launch Net Sales $M 12.0 10.0 10.4 9.4 9.0 8.0 7.8 7.6 7.9 6.0 6.8 6.4 6.1 4.0 5.0 4.7 5.0 4.4 3.7 2.0 3.0 1.3 0.0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 6 2022 Q4/YE EARNINGS

  7. Slide 7: INBRIJA Trends Since Launch

    INBRIJA Trends Since Launch TRX $M 4000 3500 3793 3464 3546 3000 3361 3319 3249 3300 3110 3070 3125 2992 2995 2500 2817 2761 2000 1915 1500 1000 500 79 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 7 2022 Q4/YE EARNINGS

  8. Slide 8: INBRIJA Trends Since Launch

    INBRIJA Trends Since Launch Cartons Dispensed to Patients $M 12000 10000 11029 10135 9924 10102 9528 8000 8883 8737 9087 8514 8305 7857 7839 6000 6909 6955 4000 4198 2000 174 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 8 2022 Q4/YE EARNINGS

  9. Slide 9: Growing the INBRIJA US Trajectory in 2023

    Growing the INBRIJA US Trajectory in 2023 2023 US net revenue guidance of $38M - $42M 2023 goal: increase patients trialing Inbrija – Inbrija has 67% market share for on-demand treatments – Only 2% of 380,000 eligible PWP are on an on-demand treatment 9 2022 Q4/YE EARNINGS

  10. Slide 10: New Brand Campaign is Having an Impact

    New Brand Campaign is Having an Impact Emphasizing the emotional impact of OFF periods on everyday activities for patients and care partners Educating on the importance of on- demand treatments Increasing investment in digital promotion Q4 vs Q3 22: returning website visitors increased 145% Q4 vs Q3

  11. Slide 11: Ampyra

    Ampyra ® 2021 Q4/YEAR END EARNINGS 11

  12. Slide 12: AMPYRA Net U.S. Sales – Q4 and YE 2022

    AMPYRA Net U.S. Sales – Q4 and YE 2022 $73M $19M 2022 Q4 2022 net sales net sales 13.7% < 2021 16.6% < 2021 2022 Guidance $68M - $78M 12 2022 Q4/YE EARNINGS

  13. Slide 13: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA Net Sales, $MM 70 64.2 60 50 $44.2 $40.6 $40.8 40 $37.6 30 $25.8 $27.2 $25.3 $21.8 $22.5 $21.1 $19.9 $20.3 $20.0 $18.8 20 $18.2 $14.9 10 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2022 13 2022 Q4/YE EARNINGS

  14. Slide 14: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA Annual net sales expected to stabilize at $60+M / year Field team continues to promote the brand ~200 HCPs resumed prescribing of AMPYRA in 2022 Physician and patient brand loyalty has helped to maintain access ~70% of all covered lives have access to AMPYRA1 1 MMIT Nation

  15. Slide 15: Financials

    Financials 15 2022 Q4/YE EARNINGS

  16. Slide 16: 2022 Additional / Ex-U.S. Revenue

    2022 Additional / Ex-U.S. Revenue INBRIJA ex-US $ 2.9M FAMPYRA royalty $11.7M Neurelis Inc. royalty $ 2.6M Asieris Pharma license $ 0.5M 16 2022 Q4/YE EARNINGS

  17. Slide 17: 2022 Financial Summary

    2022 Financial Summary ∆ YTD YTD ∆ ($ in millions) 4Q’22 4Q’21 Q/Q 2022 2021 YTD/YTD Net Global Inbrija Revenue 9.1 10.4 (12.5%) 30.9 29.6 4.4% Net Ampyra Revenue 18.8 22.5 (16.4%) 72.9 84.6 (13.8%) R&D 1.2 1.4 (14.3%) 5.8 10.4 (44.2%) SG&A 26.3 28.4 (7.4%) 106.3 124.4 (14.6%) GAAP Net Income (Loss)

  18. Slide 18: 2023 Financial Guidance

    2023 Financial Guidance INBRIJA U.S. net revenue $38M - $42M AMPYRA U.S. net revenue $65M - $70M Adjusted OpEx $93M - $103M Ending Cash Balance $43M - $47M 18 2022 Q4/YE EARNINGS

  19. Slide 19: 2023 Priorities to Build Shareholder Value

    2023 Priorities to Build Shareholder Value  Accelerate INBRIJA trajectory -Additional ex-US INBRIJA agreements  Maintain AMPYRA  Continued fiscal discipline -Cash flow positive 2023  ARCUS collaborations 19 2022 Q4/YE EARNINGS

  20. Slide 20: LIFE. SCIENCE.

    LIFE. SCIENCE. °

Acorda Therapeutics — Q4 2022 Earnings Presentation on 6ix